Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02146885 · ClinicalTrials.gov registry record
The Use of Diffuse Optical Spectroscopy to Characterize in Response to Weight-Loss Intervention
A clinical trial, sponsored by University of California, Irvine.
- Completed
- Registry status
- 21
- Enrollment target
NCT02146885: Completed study, sponsored by University of California, Irvine.
NCT02146885 is a clinical trial that has completed, run by University of California, Irvine. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02146885 has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
The first step in any clinical intervention against obesity involves sustained lifestyle changes. Researcher can use these strategies to beneficial the effects of weight and on cardiovascular risk. The researcher develope methods for assessing the effectiveness use optical technology to make such assessments, specifically in the area of fatty tissue can predict the effectiveness of the intervention in causing weight reduction and treating metabolic disease.
Interventions
- OTHER Weight Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-01-08 |
| Est. Completion | 2017-01-13 |
What the finished NCT02146885 record still lists
NCT02146885 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Weight Control is the first listed.
NCT02146885 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02146885 about?
NCT02146885 is a clinical study titled "The Use of Diffuse Optical Spectroscopy to Characterize in Response to Weight-Loss Intervention". The first step in any clinical intervention against obesity involves sustained lifestyle changes. Researcher can use these strategies to beneficial the effects of weight and on cardiovascular risk. The researcher develope methods for assessing the effectiveness use optical technology to make such as...
What is the current status of trial NCT02146885?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2013-01-08. Estimated completion is 2017-01-13.
What interventions are being tested in trial NCT02146885?
The interventions under investigation include: Weight Control (OTHER).
Who is sponsoring clinical trial NCT02146885?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI